Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.
Mazyar Shadman, MD, MPH
Advertisement
Articles by Mazyar Shadman, MD, MPH
Experts provide a brief overview of the current treatment landscape and unmet needs in relapsed/refractory (R/R) large B-cell lymphoma.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
3
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
4
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
5